Immunology patent intelligence

MX 2015008685

TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST.

CELGENE CORP [US] · Granted Mon Oct 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Sun Sep 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9068002

Treatment of multiple sclerosis and/or rheumatoid arthritis

Universität Regensburg · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9067989

Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9068003

Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9061016

Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease

APREA AB · Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9023984

Diagnostic and therapeutic target for autoimmune diseases and uses thereof

The Regents of the University of Colorado, a Body Corporate · Granted Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9017644

Methods of treating autoimmune disorders and/or inflammatory disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8987228

Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis

CAN-FITE BIOPHARMA LTD. · Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

AU 2013283318

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

4SC DISCOVERY GMBH [DE] · Granted Thu Jan 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8895539

Pregnancy hormone combination for treatment of autoimmune diseases

The Regents of the University of California · Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8835405

Inhibiting arthritis via injection of synergistic combination of hyaluronic acid and vitamin C and/or vitamin E

China Medical University · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8821866

Methods of treating and preventing colitis involving IL-13 and NK-T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8795656

Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody

Klinikum der Universität Regensburg · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8765125

Methods of treating autoimmune diseases with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8729039

Use of inhibitory oligonucleotides to treat autoimmune disease

The Regents of the University of California · Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8712696

Methods of prognosing a rheumatoid arthritis remission phenotype

PROGENIKA BIOPHARMA, S.A. · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8680066

Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject

The United States of America as represented by the Development of Veterans Affairs · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8673300

Therapeutic compositions and methods for the prevention of autoimmune diseases

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8658627

Pregnancy hormone combination for treatment of autoimmune diseases

The Regents of the University of California · Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8637031

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8598203

Treatment of Crohn's disease with laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8592456

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

AU 2012249536

Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

CELGENE CORP [CH] · Granted Thu Nov 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8568721

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8557806

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8529885

AAV vectors for in vivo gene therapy of rheumatoid arthritis

ACADEMISCH MEDISCH CENTRUM · Granted Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

AU 2012210489

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH [DE] · Granted Thu Aug 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Aug 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

AU 2012210491

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH [DE] · Granted Thu Aug 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Aug 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8501705

Methods and materials for treating autoimmune and/or complement mediated diseases and conditions

The Board of Regents of the University of Texas System · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8497279

Treatment for discoid lupus

Rigel Pharmaceuticals, Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8492347

Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus

The Regents of the University of California · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8455553

Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease and transplant rejection

The Regents of the University of California · Granted Tue Jun 04 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8404732

Methods of treating ulcerative colitis

LEXICON PHARMACEUTICALS, INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8377444

Therapeutic agent or preventive agent for osteoarthritis

AXIS · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8372826

Estriol therapy for multiple sclerosis and other autoimmune diseases

The Regents of the University of California · Granted Tue Feb 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8354436

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH · Granted Tue Jan 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8323617

Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

ANIKA THERAPEUTICS, INC. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8324165

Compositions for treating arthritis comprising HG1023575 polypeptide

Five Prime Therapeutics, Inc. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8314093

2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases

Rigel Pharmaceuticals, Inc. · Granted Tue Nov 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8309088

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8192741

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8178671

Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8173123

Methods of treating colitis involving IL-13 and NK-T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8158621

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8101174

Pharmaceutical compositions for treating arthritis and inflammatory disease

The Regents of the University of California · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)